Cargando…

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

SIMPLE SUMMARY: Malignant pleura Mesothelioma (MPM) is an aggressive cancer arising from the mesothelial cells of the pleura. About 80% of mesothelioma cases are linked to asbestos exposure; the remainder may be related to prior chest radiation, genetic predisposition or spontaneous occurrence. Unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagano, Maria, Ceresoli, Luca Giovanni, Zucali, Paolo Andrea, Pasello, Giulia, Garassino, Marina, Grosso, Federica, Tiseo, Marcello, Soto Parra, Hector, Zanelli, Francesca, Cappuzzo, Federico, Grossi, Francesco, De Marinis, Filippo, Pedrazzoli, Paolo, Gnoni, Roberta, Bonelli, Candida, Torricelli, Federica, Ciarrocchi, Alessia, Normanno, Nicola, Pinto, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601196/ https://www.ncbi.nlm.nih.gov/pubmed/33065998 http://dx.doi.org/10.3390/cancers12102948

Ejemplares similares

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations
por: Lorenzini, Eugenia, et al.
Publicado: (2021)

Prognostic and predictive role of [(18)F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
por: Zucali, Paolo Andrea, et al.
Publicado: (2017)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
por: Mannarino, Laura, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
por: Pezzuto, Federica, et al.
Publicado: (2021)

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
por: Ceresoli, G L, et al.
Publicado: (2014)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Caratterizzazione in campo dinamico di un composito rame - allumina: identificazione di modelli termomeccanici
por: Peroni, M, et al.
Publicado: (2009)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
por: Cedres, S., et al.
Publicado: (2021)

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
por: Li, Wei, et al.
Publicado: (2023)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
por: Canova, S., et al.
Publicado: (2022)

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data
por: Pasello, Giulia, et al.
Publicado: (2015)

The place of learning in a universal health coverage health policy process: the case of the RAMED policy in Morocco
por: Akhnif, E., et al.
Publicado: (2019)

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
por: Cedrés, Susana, et al.
Publicado: (2015)

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
por: Mendoza, Tito R., et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Deep Sequencing Analysis Identified a Specific Subset of Mutations Distinctive of Biphasic Malignant Pleural Mesothelioma
por: Torricelli, Federica, et al.
Publicado: (2020)

Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study
por: Mannarino, Laura, et al.
Publicado: (2022)

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
por: Borea, Federica, et al.
Publicado: (2023)

Prehospital randomised assessment of a mechanical compression device in cardiac arrest (PaRAMeDIC) trial protocol
por: Perkins, Gavin D, et al.
Publicado: (2010)

In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
por: Singh, Anand S., et al.
Publicado: (2018)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
por: Sarun, Kadir Harun, et al.
Publicado: (2018)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
por: Kuwata, Taiji, et al.
Publicado: (2020)

Simplified approach to ICU severity scoring with MPM and EUROSCORE
por: Reeves, JH, et al.
Publicado: (2010)

Preliminary update of the Mortality Probability Model (MPM0)
por: Higgins, T, et al.
Publicado: (2005)

A Novel Panel of Serum Biomarkers for MPM Diagnosis
por: Bonotti, A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q5kk851fif1lv4s4gqie5okmrg